Myriad Genetics, Inc. filed a Form 8-K on November 5, 2026, disclosing that it detected unauthorized access within its information technology network environment on November 2, 2026.

Key Highlights

  • Unauthorized access detected: The company disclosed it identified unauthorized access within its IT network environment on November 2, 2026.
  • Operations temporarily suspended: According to the filing, the company temporarily suspended its testing operations and order management systems as a containment measure.
  • Patient records under review: The filing states the full scope of unauthorized access remains under investigation, including whether any patient records were accessed on systems that contain patient information.
  • External experts engaged: The company disclosed it has engaged external experts to assist in the investigation.
  • Most systems restored: As of the filing date, the company reported that most of its systems have returned to normal operations.
  • No material adverse effect expected: The company stated it "does not believe the incident will have a material adverse effect on its business," though it identified this as a forward-looking statement subject to risks and uncertainties.

Myriad Genetics Discloses IT Network Breach and Ongoing Investigation

Myriad Genetics, Inc. (NASDAQ:MYGN), a Delaware-incorporated company headquartered at 322 North 2200 West, Salt Lake City, Utah 84116, filed a current report disclosing a cybersecurity incident affecting its IT network. According to the filing, the company detected the unauthorized access on November 2, 2026, and promptly initiated its incident response procedures upon discovery.

The company disclosed that its response included containing the activity, assessing and investigating the nature and scope of the incident, implementing remedial measures, temporarily suspending testing operations and order management systems, and resetting certain system credentials. The filing notes that external experts have been engaged to assist in the investigation. As of the report date, most of the company's systems had returned to normal operations.

The filing states that the full scope of unauthorized access remains under investigation, specifically including an assessment of whether any patient records were accessed on systems that contain patient information. The company disclosed it does not believe the incident will have a material adverse effect on its business, while also noting in its cautionary language that this belief is a forward-looking statement subject to risks including legal, regulatory, reputational, and financial risks resulting from the incident or additional incidents. The report was signed by Benjamin R. Wheeler, Chief Financial Officer, on November 5, 2026.

What Was Disclosed

Myriad Genetics reported a November 2, 2026 unauthorized access event in its IT network, disclosing temporary suspension of testing and order management systems, an ongoing investigation into potential patient record exposure, and engagement of external experts to assist.